Название продукции:2,3-Dichloropyrido[3,4-b]pyrazine
IUPAC Name:2,3-dichloropyrido[3,4-b]pyrazine
- CAS：35251-99-1
- Молекулярная формула：C7H3Cl2N3
- Чистота：95%+
- Номер в каталоге：CM332598
- Молекулярная масса：200.02
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:35251-99-1
- Молекулярная формула:C7H3Cl2N3
- Точка плавления:-
- Smiles-код:ClC1=NC2=CN=CC=C2N=C1Cl
- Плотность:
- Номер в каталоге:CM332598
- Молекулярная масса:200.02
- Точка кипения:
- Номер Mdl:MFCD19374272
- Хранение:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
- Pyrazines
- Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.
- pyrazine,pyrazine price
- if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.
Column Infos
- CVN424
- In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Поиск 
+86 21 5895 0110 
